Table 2. Adjusted hazard ratio associated with a 100-mSv increase in cumulative exposure.

	Minimum latent period 10 years assumed for solid cancer and 2 years for leukaemia				Minimum latent period 5 years assumed for solid cancer and 2 years for leukaemia
Cancer site	Casea	HR100mSvb	90% CIb	P-valueb	Casea	HR100mSvb	90% CIb	P-valueb
All cancers	249	1.05	(1.00, 1.08)	0.04	282	1.05	(1.00, 1.08)	0.03
All cancers excluding leukaemia	241	1.04	(1.00, 1.08)	0.08	274	1.04	(1.00, 1.08)	0.05
All solid cancers	236	1.04	(1.00, 1.08)	0.07	269	1.04	(1.01, 1.08)	0.04
Female breast	35	1.11	(1.05, 1.20)	0.008	40	1.12	(1.04, 1.17)	0.002
Cervix uteri	24	1.10	(0.96, 1.20)	0.10	28	1.09	(0.97, 1.17)	0.13
Lung	24	1.10	(1.00, 1.17)	0.05	27	1.12	(1.04, 1.18)	0.004
Thyroid gland	20	1.06	(0.83, 1.17)	0.52	25	1.03	(0.80, 1.15)	0.75
Liver	18	1.05	(0.88, 1.15)	0.52	19	1.04	(0.88, 1.14)	0.57
Stomach	13	1.08	(0.92, 1.19)	0.27	15	1.10	(0.97, 1.19)	0.10
Rectum	16	1.03	(0.73, 1.17)	0.78	17	1.02	(0.71, 1.16)	0.87
Leukaemia excluding MM&CLLc	8	1.18	(1.04, 1.28)	0.006	8	1.18	(1.04, 1.28)	0.006
Leukaemia excluding CLL	11	1.15	(1.03, 0.24)	0.012	11	1.15	(1.03, 1.24)	0.012

^aCancers with minimum latent periods (leukaemia:2 years; solid cancers:10 years or 5 years).

^bHR were adjusted for initial exposure age, 90% CI were partial likelihood-based, and P-values were two-sided.

^cCLL=chronic lymphocitic leukaemia; MM=multiple myeloma.